| Abstrakt: |
The evidence on the treatment of 146 cases of blastic (myeloid-101, lymphoblastic-45) crisis (BC) have been analyzed to evaluate the efficacy of different schemes of polychemotherapy (PCT) administered for blastic crisis myeloid leukemia (CML). The study of the 7 + 3, 7 + 3 + B. RP, VRP, RAP, VAP, CROMP. COP + Rub schemes as well as large doses of cytosar showed the 7 + 3 and RAP to be the most effective for myeloid BC and COP + Rub and VAP-for lymphoblastic one. Complete clinico-hematologic remission was 55 and 56%, respectively, in myeloid BC and 50 and 57%, respectively, in lymphoblastic BC. Relatively lower antitumor effect was recorded for the CROMP and RP in myeloid and the VRP in lymphoblastic crisis. Actuarial survival was assessed both for the entire CML group and each type of crisis and PCT scheme, and it was shown that more cases of lymphoblastic BC survived while fewer of them survive 3-5 years. However, 6-year survival rates were identical in both groups. Survival in the 7 + 3 group appeared to be higher than that in the VRP group suffering from lymphoblastic. BC. To summarize, the 7 + 3 and RAP schemes proved the most effective treatment for myeloid BC, while the COP + Rub and VAP for lymphoblastic BC. |
